Science to Practice: Will Randomized Prospective Clinical Trials Be Necessary for RF Ablation of Large Liver Tumors with Liposomal Doxorubicin?

Abstract

HomeRadiologyVol. 255, No. 1 Next SCIENCE TO PRACTICEScience to Practice: Will Randomized Prospective Clinical Trials Be Necessary for RF Ablation of Large Liver Tumors with Liposomal Doxorubicin?Evan C. UngerEvan C. UngerEvan C. UngerPublished Online:Mar 10 2010https://doi.org/10.1148/radiol.092424MoreSectionsFull textPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In AbstractThe study by Solazzo et al, defining the mechanisms of cell stress and repair, provides a scientific backstop to help support the clinical use of liposomal doxorubicin at radiofrequency ablation.References1 Solazzo S, Ahmed M, Schor-Bardach Ret al.. Liposomal doxorubicin increases radiofrequency ablation–induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 2010;255(1):62–74. Link, Google Scholar2 Curley SA. Radiofrequency ablation of malignant liver tumors. Oncologist 2001;6(1):14–23. Crossref, Medline, Google Scholar3 Chen MH, Yang W, Yan Ket al.. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model, overlapping mode, and electrode placement process. Radiology 2004;232(1):260–271. Link, Google Scholar4 Goldberg SN, Girnan GD, Lukyanov ANet al.. Percutaneous tumor ablation: increased necrosis with combined radiofrequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002;222(3):797–804. Link, Google Scholar5 Goldberg SN, Kamel IR, Kruskal JBet al.. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002;179(1):93–101. Crossref, Medline, Google Scholar6 Doxil. Centocor Ortho Biotech Products. http://www.doxil.com/assets/DOXIL_PI_Booklet.pdf. Accessed September 2009. Google Scholar7 Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003;8(suppl 2):3–9. Crossref, Medline, Google ScholarArticle HistoryPublished online: Mar 10 2010Published in print: Apr 2010 FiguresReferencesRelatedDetailsRecommended Articles Therapeutic Effects of CT-guided Radiofrequency Ablation with Concurrent Platinum-Doublet Chemotherapy in a Rabbit VX2 Lung Tumor ModelRadiology2016Volume: 283Issue: 2pp. 391-398Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency AblationRadiology2017Volume: 286Issue: 2pp. 524-536Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor GrowthRadiology2016Volume: 281Issue: 3pp. 782-792Radiofrequency Ablation Followed by Surgical Excision versus Lumpectomy for Early Stage Breast Cancer: A Randomized Phase II Clinical TrialRadiology2018Volume: 289Issue: 2pp. 317-324Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?Radiology2017Volume: 285Issue: 2pp. 333-335See More RSNA Education Exhibits Novel Image-Guided Micro-Invasive Percutaneous Treatments of Breast Lesions: Where Do We Stand?Digital Posters2019The Fast and the Furious: Rapid Progression of HCC After Locoregional Therapy — A Tri-Institutional Collaboration on Imaging PatternsDigital Posters2018Imaging Follow-Up After Radiofrequency Ablation (RFA) in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC): An Experience-Based Pictorial ReviewDigital Posters2018 RSNA Case Collection Solitary breast plasmacytomaRSNA Case Collection2021AIDS-associated Kaposi sarcomaRSNA Case Collection2020Medication Related Osteonecrosis of the Jaw RSNA Case Collection2021 Vol. 255, No. 1 Metrics Altmetric Score PDF download